Internal Medicine & Patient Care

Michael S. Bronze, M.D. was appointed Professor and Chairman, Department of Medicine, University of Oklahoma Health Sciences Center effective July 1, 2000. He was named the Stewart G. Wolf Professor in Internal Medicine in 2004 and David Ross Boyd Professor in 2011. He is board certified in Internal Medicine and Infectious Diseases. He completed his medical school training at the University of Tennessee, Memphis in 1982. His internship and residency were completed at the University of Tennessee, Memphis and served and additional year as Chief Medical Resident. Dr. Bronze completed a fellowship in Infectious Diseases also at the University of Tennessee, Memphis from 1986 through 1988. Following his professional training he was appointed as an Instructor, Division of Infectious Diseases, University of Tennessee, Memphis in 1987. Over the ensuing years he was promoted to Professor of Medicine, University of Tennessee, where he served until June 30, 2000. His research interests have included the pathogenesis of the nonsuppurative complications of group A streptococcal infections, the role of inflammatory cytokines in bacterial growth, bioterrrorism and more recently the pathogenesis of hepatocellular carcinoma in patients with hepatitis C infection. He has published more than 200 manuscripts, abstracts and book chapters. Dr. Bronze has served numerous administrative and educational capacities including: Associate Chief Medical Officer, UT Medical Group from 1999 – 2000; Associate Chairman, Clinical Operations, Department of Medicine, University of Tennessee, Memphis from 1997 – 2000; Co-Director, University of Tennessee Infectious Diseases Fellowship Program, 1991 – 2000; Director, University of Tennessee Internal Medicine Residency Program, 1993 – 1997; Chief of the Medical Service OU Medical Center 2000-present; and Interim Chief Medical Officer OU Medical Center 2007-2009. He serves on the editorial board and as a reviewer for numerous journals and has been a chair or officer of numerous local, national and regional committees and professional societies including President of the Southern Society for Clinical Investigation 2004-2005, President of the Association of Professors of Medicine 2012-2013 and Chair of the Board of Directors of the Alliance for Academic Internal Medicine 2013-2015. He has been active in the National Board of Medical Examiners (USMLE) and is a former member of the Executive Committee of the Board of Governors for the American College of Physicians as well as other committees. He has been elected a Master of the American College of Physicians and a Fellow of the Infectious Diseases Society of America.

Internal Medicine, Prevention of group A streptococcal infections, Emerging pathogens, General Infectious Diseases, HIV, Graduate medical education

William J. Rowe M.D. FBIS ( Fellow British Interplanetary Society ), FACN ( Fellow American College of Nutrition ), is a board certified specialist in Internal Medicine. He received his M.D. at the University of Cincinnati and was in private practice in Toledo, Ohio for 34 years. During that time he supervised over 5000 symptom - limited maximum hospital-based treadmill stress tests. He is a former Assistant Clinical Professor of Medicine at the University of Ohio, School of Medicine at Toledo. He studied 3 world class extraordinary endurance athletes and published their exercise---related magnesium deficiencies. This triggered a 20 year pursuit of the cardiovascular complications of Space flight. He has published in LANCET that extraordinary, unremitting endurance exercise can injure a perfectly normal heart. Of only 4 space syndromes, he has published 2: "The Apollo 15 Space Syndrome" and "Neil Armstrong Syndrome." He published Neil Armstrong's probable lunar acute heart failure. He has been listed in the Marquis Whos Who of the World from 2002-2009,2013, 2014, 2015, 2016, 2017.

Cardiovascular complications of space flight, focusing particularly on catecholamine cardiomyopathy, impaired thermoregulation and “Neil Armstrong Syndrome.: severe dyspnea, thirst, tachycardia with the latter corrected by restoring plasma volume.

Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA. His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc. He has participated at more than one hundred fifty reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Indexing (ISI) Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Australia, Scotland, Ireland, Netherlands, Belgium, Denmark, Greece, Russia, Estonia, Turkey, France, Swiss, Germany, Sweden, Italy, Austria, Hungary, Poland, Spain, Portugal, Mexico, Japan, Malaysia, Thailand, Taiwan, South Korea, China, India, Qatar, United Arab Emirates, etc. as research fellow, sabbatical and volunteer researcher or visitor and so on heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than seven hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals, books and publishers. Hitherward, he is a member of more than two hundreds reputed international academic–scientific–research institutes around the world. In addition, he is member of the Nobel committee for Chemistry. It should be noted that he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the BioSpectroscopy Core Research Laboratory at California South University (CSU), Irvine, California, USA.

Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure, Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells

Reza Nassiri is an Associate Dean of Global Health, Director of Institute of International Health, Professor of Clinical Pharmacology, Professor of Family and Community Medicine and Lecturer in Global Health, Infectious Diseases and Tropical Medicine at Michigan State University College of Osteopathic Medicine. His research interests focuses on Clinical Pharmacology of HIV/AIDS & TB, prevention and control of infectious diseases, neglected tropical diseases, community health, global health and socio-ethical determinants of health. He works on international public health issues and has expertise in global health education, research, policy and governance. He has made contributions in various fields of medical sciences including clinical investigation and health education. On the basis of his extensive experience and expertise in HIV/AIDS and TB, he developed Clinical Research Programs in Brazil, South Africa, Haiti, Dominican Republic and Mexico

international health initiatives, health in developing nations, HIV/AIDS research

Dr. Rao, Ph.D, worked as professor of Microbiology, Parasitology, Immunology and Epidemiology in many universities, many medical colleges in India, China, Nepal, Libya, and Philippines. Currently he is working as professor of Microbiology, Parasitology, Immunology and Dean (Student Affairs) at Avalon University School of Medicine, Curacao, Netherland Antilles. Dr. Rao has more than 42 years of teaching and research experience. Supervised 3 students for Ph.D, 4 students for M.Phil, 4 students for pre M.Phil degrees. 3 students submitted their Ph.D thesis to Acharya Nagarjuna University, Guntur, Andhra Pradesh, India and waiting for viva examination and degree. Authored 18 text books. 3 Universities appointed as their adviser and 3 universities honored with fellow ships. Presented 8 full length papers exclusively during 2014 to 2015 in different international journals.In 2016 ,January and February presented two full length papers in international journals .Accepted as organizing committee member for 3 international conferences in 2016 and Invited speaker for 8 conferences, in different countries like Manchester,(UK), Birmingham,(UK), Atlanta (US), Dubai,(UAE),Rome,(Italy),Amsterdam(Netherland) etc.

Parasitology, Microbiology,Biotechnology Virology,Molecular immuno diagnostics, Public health, and epidemiology .Parasitic infections are more in tropical countries and cause global health problem especially in developing countries. High level innovation centered on genomics, RNA biology,Systemic biology, Stem cell biology,Nano science, novel animal models , strategic focus is on technology development in the ares of bio therapeutics , bio markers,bio sensors, bioequipments implants devices , advanced diagnostics, tests, vaccines, therapeutics and development of new drugs are needed. Viviparity is common among est mammals but not many provide long gestation period, To study long term parasitic toxic effects, it is essential to use long gestation period laboratory animal models. Rats have 21 days, rabbits 30,dog 60 days of gestation period, The subtle effects of Thalidomide tragedy resulting in phocomalia, apoda etc in the offspring lead to untold miseries, Similarly good number of cases of fetal deaths, still births, teratogenices etc. Dr.Rao used scorpion as research model as it has nearly 10 months gestation period , in estimation of heavy metals like mercury and lead in embryonic development of scorpion and noticed similar effects, Indeed great challenges, given that most drugs in pipe line failed in clinical trails. Because most of the drugs tested on low gestation period animals, A new thought in the drug design for parasitic diseases by using scorpion as a medical research model. Introducing parasite in scorpion and observing the drug effects and reversal effects . In addition to clinical work, developed a variety of basic and transnational research programs, participated to Ph.D. programs.

Dr Sergey Suchkov, MD, PhD. Professor in Medicine. Director, Center for Personalized Medicine, I.M.Sechenov First Moscow State Medical University, and Chair, Dept for Translational Medicine, Moscow Engineering Physical Institute (MEPhI). Born 11.01.1957, Astrakhan, Russia; two sons. Education: MD, Astrakhan State Medical University, Russia, 1980; PhD, I.M.Sechenov First Moscow State Medical University, 1985; Doctor Degree, Nat Inst of Immunology, Russia, 2001. Positions held: Post Doc Research Associate, Inst of Med Enzymology; Head of the Lab of Immunology, Helmholtz Eye Research Inst in Moscow; Trainee: NEI, NIH, Bethesda, MD, USA; Chair, Dept for Clin Immunology, Moscow Clin Research Inst (MONIKI); Exe Secretary-in-Chief of the Editorial Board, Biomedical Science International; Director, the Center of Personalized Medicine, I.M.Sechenov First Moscow State Medical Univ, and Chair, Dept for Translational Medicine, Moscow Engineering Physical Institute (MEPhI). Honours: Secretary General, United Cultural Convention (UCC), Cambridge, UK. Memberships: New York Academy of Sciences, USA; ISPM, Tokyo, Japan; PMC, Washington, DC, USA; ACS, USA; AMEE, Dundee, UK; AHA, USA; EPMA, Brussels, EU.

Personalized, Precision and Translational Medicine, Immunology and Immunogenetics

Prof. D. Roukos has graduated from Athens University School of Medicine, Greece. He underwent specialist training in surgery at the J.W.Goethe-University Hospital in Frankfurt a.M., Germany where received his Doctorate (Dr.med). He moved back to Greece and since 1990 works at the Ioannina University School of Medicine. Currently he is a Professor of Surgery and Precision Cancer Genome Medicine and Founding Director of Centre for BioSystems and Genome Network Medicine, Ioannina University, School of Medicine, Greece. He has published 231 papers in PubMed including 80 on clinical cancer genome analysis applying Next - Generation Sequencing, molecular interactions regulatory networks and nonlinear transcriptional biocircuits for clinical implications as well as 30 on Precision Medicine - Oncology. He is a reviewer in multiple high-impact international Journals including Nat Biotech, Nat Rev Genet, Nat Protocol, Lancet Oncology, Nat Rev Clin Oncol etc. He is an Editorial Board Member in <20 PubMed and ISI indexed Journals.

Clinical cancer genome analysis applying NGS, molecular interactions regulatory networks and nonlinear transcriptional biocircuits for clinical implications, Precision Medicine - Oncology

Vasiliki E. Kalodimou is Director of the Flow Cytometry-Research and Regenerative Medicine Department at IASO Maternity-Pediatric and Research Hospital in Athens, Greece. Before her current appointment, Kalodimou served as a haematology associate at General University Hospital of Heraklion, Crete, and as an instructor at both the General University Hospital of Heraklion and the Ipokratios Medical- Technical Institute of Athens. Kalodimou received her bachelor’s degree in Human Physiology and her master’s degree in Human Molecular Genetics from the Imperial College at the University of Medicine in London, UK. She completed her PhD at the University of Medicine in Athens, Greece, with an emphasis on stem cells and factors affecting their viability and absolute numbers.

Since 2006, Dr. Kalodimou has studied and working with stem cells from placenta, umbilical cord and adipose tissue, in every day practice and their applications in regenerative medicine and Flow Cytometry. Also is working in the area of human genetics & population genetics. In collaboration with the Hellenic Flow Cytometry Society, Kalodimou has developed quality control schemes for stem cell marker enumeration. The goal of this work is to find helpful new applications for flow cytometry, evaluate the risk factors for stem cell infusion, and improve the clarity and accessibility of measurements by flow cytometry. Her work quantifies and ranks all risks of flow cytometry enumeration to prevent and minimize the false-positive results from different cytometer uses. She is also working to establish combinations of monoclonal antibodies for mesenchymal and adipose tissue stem cell enumeration. In addition to collaboration with state universities and pharmaceutical companies on research projects, Kalodimou frequently publishes her findings. The Greek edition of the book was published in 2010 and has been well-received while in 2013 the English edition of the book was puplished by AABB Press USA. She is a member of two subsections of the AABB Cellular Therapies Section and also an AABB assessor.

Full Professor of Internal Medicine, University of Granada, Spain; Chief of the Service of Internal Medicine, San Cecilio Clinical Hospital Granada and the Hypertension Unit (1982-2014); Principal Investigator of more than 150 international and multicentric clinical trials mainly on cardiovascular risks factors. Chairman of the Department of Medicine (1986-1993/2001-2009); President of the Spanish Society of Internal Medicine (1996-1998); President of the 27th World Congress of Internal Medicine (Granada, 2004), Honorary Member of the International Society of Internal Medicine (2004), and Member of the Royal Academy of Medicine, Granada (1991-).

Hypertension, Diabetes Mellitus, and Lipid Disorders

Dr. Ellahham has served as Chief Quality Officer for SKMC since 2009. He is a recognized leader in quality, safety, patient experience, risk management and the use of robust performance improvement in improving healthcare delivery. He serves on a number of US and international committees and advisory bodies. He is the Middle East Regional Chair of the Patient Safety Movement Foundation. HE is a Certified Professional in Healthcare Quality (CPHQ) by The National Association for Healthcare Quality (NAHQ). He is certified in Medical Quality (CMQ) by The American Board of Medical Quality (ABMQ). He is the recipient of the Quality Leadership Award from the World Quality Congress and Awards and the Business Leadership Excellence Award from World Leadership Congress in 2015. He is one the nominees for Safe Care magazine Person of the Year in the United States. Dr. Ellahham is the recipient of prestigious SKMC Infection Prevention Award in 2011 and 2012. He is recognized worldwide for Excellence in infection prevention and control. Dr. Ellahham is Middle East Representative of the JCI Standards Subcommittee and Member on the Editorial Advisory Board of the Joint Commission Journal on Quality and Patient Safety. He is reviewer of HCAC Cardiac Quality and Safety Standards. Dr. Ellahham has been a champion of the use of Lean, Six Sigma and Change Management to improve healthcare quality. He is Lean Six Sigma Master Black Belted. He was the Leader of the First Pilot International Robust Process Improvement (RPI) project by the Joint Commission Center for Transforming Healthcare and several other similar successful performance improvement projects at SKMC. He is Lead Trainer in TeamSTEPPS Lead Trainer. Dr. Ellahham is certified as EFQM 2013 Model assessor and is leading EFQM Excellence Model at SKMC with great success including winning the prestigious Sheikh Khalifa Excellence Award in 2014, Dubai Quality Award in 2015 and Sheikh Khalifa Excellence Golden Award in 2015. Dr. Ellahham is the Executive SKMC sponsor of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) the leading US validated, risk-adjusted, outcomes-based program to measure and improve the quality of surgical care. SKMC is the first multispecialty ACS NSQIP center outside the US. Dr. Ellahham led the publication of, first in the region, annual SKMC outcome books since 2011. He is a strong believer in transparency in health care and external reporting. Dr. Ellahham is a Board-certified internist, cardiologist and vascular medicine senior consultant and continues to care for patients. He received his undergraduate degree in biology and his M.D. from the American University of Beirut. He did his fellowship in Cardiology at the Medical College of Virginia (MCV) in USA. After completing his fellowship, Dr. Ellahham worked in Washington DC in several clinical and leadership positions before moving to UAE in 1988. He led the First AHA GWTG Heart Failure Initiative outside US and was the recipient of the AHA GWTG Award in Wash. DC. His clinical passion and expertise is in the field of heart failure management. He demonstrated great skill and experience in the management of patients with heart failure and led a multi-disciplinary team in the care and delivery of advanced therapies to these patients. He has unique abilities to partner and engage local and regional referring providers. He is able to work in a highly matrixed environment, possess strong leadership and organizational skills and have experience to working effectively in a large health system. He is currently Cleveland Clinic Staff and on the Executive Team of The Cleveland Clinic Foundation, in Abu Dhabi, UAE. Dr. Ellahham is a fellow of the American College of Cardiology, American College of Chest Physicians, American College of Physicians, and American Heart Association. He is the Eminent Editor of The Journal of Cardiology & Cardiovascular Therapy. In addition, he serves is on the editorial board of the Joint Commission Journal on Quality and Patient Safety, Open Access Journal of Clinical Trials, Hypertension Today Journal and Focus on Hypertension Journal. Dr. Ellahham is a Distinguished Fellow of the New Westminster College in British Columbia, Canada. Dr. Ellahham is an avid researcher; his research includes lean six sigma, change management, innovation, safety, outcomes research, risk management, safe surgery, heart failure, diabetes mellitus, genetics, cardiac imaging, sports and nutrition. He is a recognized world-leader in these fields. He received several research awards including the DuPont Pharmaceuticals Research Award, ACCP 58th Annual Scientific Assembly, Young Investigator Award; the Alfred Soffer Research Award, ACCP 58th Annual Scientific Assembly, Finalist; the First Young Investigator Award 12th, Annual Meeting of the Mediterranean Association of Cardiology and Cardiac Surgery, and the American Heart Association Get with the Guidelines Award. Dr. Ellahham is on the editorial board of Medical Science, Open Journal of Cardiatic Research and was on the editorial board of The Joint Commission Journal on Quality and Patient Safety. He is also a reviewer for several peer-reviewed journals, including Joint Commission Journal on Quality and Patient Safety, International Journal of Quality & Reliability Management, the Journal of American College of Cardiology, the American Heart Journal, Annals of Internal Medicine, Archives of Internal Medicine, Chest, Circulation, Clinical Cardiology, Chest, Lancet ,Diabetes Care, Archives of Internal Medicine, Endocrinology and Metabolism, European Journal of Heart Failure, Congestive Heart Failure Journal, Journal of Nuclear Cardiology, the Journal of Transplant Coordination, the Journal of Cardiovascular Pharmacology and the Southern Medical Journal, European Journal of Innovation Management and The Anatolian Journal of cardiology.

Lean six sigma, change management, innovation, safety, outcomes research, risk management, safe surgery, heart failure, diabetes mellitus, genetics, cardiac imaging, sports and nutrition

Biography (Max. 250 words) Personal Statement My research focuses on the genetic mechanisms and regulatory pathways involved in pulmonary disease. In my graduate study I had focused on the role of microRNAs and epigenetic regulators in disease pathology. Specifically, we had identified alterations in gene regulation that correlates with clinical severity of disease in IPF. This has allowed us to target potential therapies, some of which have shown significant promise in our small animal models. While my current focus is on patients with IPF, these pathways allow diverse application too many fields of study. We have developed several collaborations with clinicians and researchers a like examining epigenetic regulation in diseases such as breast cancer, sepsis and acute respiratory distress syndrome. The central theme of my research is to identify epigenetic mechanisms by which prolonged macrophage survival can amplify the immune response and contribute to cancer, metastasis, Autophagy, chronic lung inflammation in idiopathic pulmonary fibrosis (IPF) and other inflammatory lung diseases. Thus, my research focuses on two projects involving microvesicles and epigenetic regulation. We currently are examining the interplay of DNA methyltransferases and microvesicles in cancer and inflammation. We have several collaborative efforts with colleagues within the University and my former mentors as well with the Institute for Systems Biology. Currently, we are investigating how macrophages communicate via secreted microvesicles (MVs) which are taken-up by neighboring epithelium. Since July 2013 I was added to the Oncology T32, and had generated data demonstrating that MVs contain mRNAs coding the epigenetic regulating machinery, DNA methyltranferases (DNMTs) and histone deacetylases (HDACs), which regulate promoter CpG island methylation and resulting gene expression of tumor suppressor genes (TSGs) and genes driving epithelial-to-mesenchymal transition (EMT) in epithelial cells. This data was accepted as both a poster and short talk format for the 2014 AACR Cellular Heterogeneity in the Tumor Microenvironment in San Diego, CA February 26. Duaa will also be presenting this work in poster form at the OSUCCC – James 16th Annual Scientific Meeting on February 28. Furthermore, we reported that activation and stabilization of a hypoxia-inducible transcription factor (HIF-2 alpha) with a novel PHD3 inhibitor slows tumor growth and angiogenesis in melanoma. Formerly, the HIF proteins were thought to be pro-angiogenic in the hypoxic conditions of solid tumors. We recently developed a new and unique transgenic mouse model with conditional TIE2 receptor knock out in the myeloid cell lineage, LysMcre/TIE2 floxed. These tumor-bearing mice (either by orthotopic mammary gland injections or crossed with MMTV-PyMT spontaneous breast cancer mice), lack the pro-angiogenic macrophage phenotype known as “TIE2-expressing monocytes/macrophages”, or TEMs. We developed this transgenic mouse model to demonstrate a causal role for TEMs in the growth, progression, angiogenesis, and metastasis of breast cancer. Information gained from these mice will be used to develop new treatment possibilities for breast cancer patients. Another part of the program involves our work with AKB-6899, a novel small molecule inhibitor of prolyl hydroxylase-3 (PHD3) and stabilizer of HIF-2alpha. We reported that AKB-6899 can induce soluble VEGF receptor-1 (sVEGFR-1) expression from tumor macrophages, sequestering tumor- and macrophage-derived VEGF bioactivity resulting from hypoxia. Furthermore we found that AKB-6899 has an epigenetic effect on many oncogenes and EMT pathway. Through a sponsored research program and funding from Akebia Therapeutics, we are performing pre-clinical testing on human tumor xenografts in SCID mice to get IND and FDA-approval of AKB-6899 for use in non-small cell lung cancers into clinical trials. We have also established collaborations with experts in RNA-binding and chemical engineering to investigate aspects of miRNA/mRNA/protein packaging to the microvesicles. Thus, in summary, my funding and publication record underscores my technical capabilities and scientific achievements. As described in the proposal, our collaborative efforts on this proposal will enable us to perform preclinical testing of exciting new treatments for patients with breast cancer who otherwise have weak inefficient options clinically. Positions Research Assistant Professor, West Virginia University 2015-present Assistant Professor, American University of Middle East 2014-2015 Post-Doctoral Researcher, Ohio State University, 2011-present Graduate Research Assistant, Ohio State University, 2006-2011 Graduate Student Assistant, Ohio State University, 2007-2008 Research Assistant, Ohio State University, 2001-2005 School Manager, Islamic School, 2002-2004 Research Assistant, Al-bayt University, Jordan, 1993-1994 Teaching Assistant, Mu’tah University, Jordan, 1991-1994 Laboratory Assistant, Mu’tah University, Jordan, 1991-1992

Research Interest Molecular genetics, epigenetics, DNA methylation, lung fibrosis, sepsis, microvesicles, miRNA, IPF, HDACs, DNMTs, Aging, Cystic Fibrosis.

I was born in Çankırı/Turkey in 1976. I was graduated in 2009 from Ankara University School of Medicine Pulmonary Diseases Department and since 2011, I have been working as an interventional pulmonogist in Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital. I am a member of ERS, ATS, EABIP, WABIP, Turkish Thoracic Society and Turkish Respiratory Society. Also I am still a member of Turkish Respiratory Society 39th YEAR National Congress Organizing committee and in charge of the courses.

Interventional Pulmonology, lung cancer

Zeliha Selamoglu is a Professor in Medical Biology Department in Medicine Faculty of Nigde Ömer Halisdemi rUniversity, Turkey. She earned her PhD in Inonu University, She has published over 70 peer reviewed journal articles withover 500 citations and many technical reports. She is a member of Society for Experimental Biology and Medicine: Associate Membership and European association for cancer research. She has served as Editorial Board member fo rmany Journals.

Medical Biology, Molecular Biology, Biochemistry, Biotechnology, Oxidative stress, Antioxidants, Cancer

Dr . Seemin Afshan Shiraz completed her MRCP(UK) in 2007 and then European Diploma in Critical Care in 2009. She has extensive experience in internal medicine and critical care. She has been invoved in teaching of medical students at University of Sharjah along with the training and teaching of post graduate students of family medicines, internal medicine and critical care medicine. She as an ACLS instructor. She has been taking part in several oral and poster presentations both at national and international level. Currently, she is working as an incharge of a critical care fascility in Dubai, United Arab Emirates.

Acute Medical Emergencies, vitamin D, Diabetes Mellitus

Biography Dr. Mukesh Singh Sikarwar is currently working as Senior lecturer in Faculty of Pharmacy, AIMST University, Malaysia. He has served as organizing secretory in Falling Walls Lab Malaysia 2016 and 2017 hosted at AIMST University. He was invited as Keynote speaker and Co- Chair 2nd Global Summit on Herbals & Natural Remedies October 17-19, 2016 Kuala Lumpur, Malaysia. He was invited as plenary speaker at University of West Indies and participation was fully sponsored by organizers. Dr. Sikarwar selected as finalist of Falling Walls young innovator of the year 2015 at Berlin, Germany, and participation was fully sponsored by falling walls foundation Germany and its partners. He was selected to present research in Innovation challenge at Yayasan Inovasi Malaysia, MOSTI. He has developed MOOC course titled "Breadfruit nutritional and medicinal values" over the platform of www.openlearning.com He received his PhD in Pharmacy from K.L.E. University, Belgaum India in year 2011. His current area of research is herbal antioxidants, antidiabetics and antihyperlipidemics, novel drug delivery in herbal drugs, formulation and evaluation of herbal drugs and food safety. He has more than 11 year of experience in mentoring students in Pharmacognosy and chemistry subjects. He has published 58 research and review papers in various peer reviewed internationals and national journals and also serving as reviewer for many international journals. He has presented 29 research papers in various national and international conferences. He has preapred MOOC course on breadfruit. He has attended many MOOC courses and Online CME from online learning programmers. He is a life member of APTI, member of Asian Council of Science Editors and registered as pharmacist with M. P. State Pharmacy Council.

Pharmacognostic study and antioxidant potential of unexplored Malaysian plants, Herbal Antidiabetics and Herbal Antihyperlipidemics, Novel drug delivery in Herbal drugs, Formulation and evaluation of herbal drugs, Breadfruit research